Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Prescription Required
bms india
60 tablet
Dasatinib
Keep in cold place
Delivering To:
Overview
The Sprycel 70mg Tablet is used to treat chronic myeloid leukemia, or blood cancer. Patients who are unable to take other leukemia medications due to adverse effects or whose disease cannot be treated with them are treated with it. It is a member of the class of drugs called protein-tyrosine kinase inhibitors. This medication functions by preventing the abnormal protein that instructs cancer cells to proliferate from doing its job. It is crucial that you take this medication exactly as directed by your physician. While taking this medication, blood cell counts must be closely monitored.
Blood Cancer
Blood cancer (Chronic myeloid leukaemia)
Sprycel may cause some common side effects. Before starting treatment, discuss the risks and benefits of Sprycel tablets, as well as your medical history, with your doctor.
Bleeding gums
Constipation
Coughing up blood
Body pain
Dizziness
Weight gain
Irregular heartbeat
Sore throat
Headache
Nasal congestion
Anemia
Fatigue
Nausea
Infection
Low blood platelets
Take Sprycel 70mg Tablet as prescribed by your doctor. Do not stop or skip your regular dosing schedule. In case of an overdose of Sprycel tablets, the doctor will provide emergency medical treatment.
Acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML) cell lines that overexpressed BCR-ABL were reduced in their proliferation by dasatinib. Dasatinib successfully overcame imatinib resistance caused by mutations in the BCR-ABL kinase domain, activation of alternative signaling pathways involving the SRC family kinases (LYN, HCK), and overexpression of multi-drug resistance genes under the assay conditions. The effects of this medication can be seen one to six hours after oral consumption.
Alcohol
unsafe
It is advisable not to consume alcohol while taking this medicine.
Pregnancy
consult your doctor
Do not take Sprycel 70mg Tablet without consulting the doctor, in case of pregnancy.
Breast Feeding
consult your doctor
Without a doctor's consultation, do not take this medicine if you're breastfeeding.
Driving
danger
It is advisable not to drive or operate heavy machinery, you may feel dizzy as one of the side effects of the medicine.
Kidney
caution
Do not consume Sprycel 70mg Tablet without a doctor's consultation in case of kidney problems.
Liver
caution
Share your medical history with the doctor in case of liver disease before taking this medicine.
It is advisable not to miss a dose. If you miss a scheduled dose of Sprycel tablets, contact your doctor immediately.
This medicine is used for the treatment of blood cancer, and it helps to prevent the growth of cancer cells.
Some common side effects of this medicine are bleeding, constipation, weight gain, sore throat, dizziness, fatigue, anemia, etc.
This medicine works by blocking the action of the abnormal protein that signals cancer cells to multiply.
It is advised not to drive after taking Sprycel 70mg Tablet. This medicine may affect your vision and your ability to concentrate.
Follow your doctor’s advice about any restrictions on food and other activities.
At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.
Enjoy the convenience of fast home delivery, secure packaging, and affordable prices*—plus *special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.
Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.
We Currently Ship To:
Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!
D., Cheng, H., Guo, J., Jiang, R.,Zhang, Y., Wan, C., Qin, J., Yuan, G., Chen, S., Yang, Z., Hu, J., Zhang, Y., & Li, W. (2023). 1-year results of dasatinib 70 mg/day versus 100 mg/day in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML‑CP): A prospective randomized controlled study. Hemasphere, 7(Suppl), e8560105. https://doi.org/10.1097/01.HS9.0000969568.85601.05
Silver, R. T., et al. (2006). Dasatinib (SPRYCEL®) 70 mg twice daily versus other dosing schedules in patients with imatinib-resistant or intolerant CML‑CP: Results from CA180‑034 (START‑C). Blood, 108(11), 166. https://doi.org/10.1182/blood.V108.11.166.166.
Kantarjian, H. M., et al. (2023). Low-dose dasatinib (50 mg daily) frontline therapy in newly diagnosed CML‑CP: 5‑year follow-up results. https://pubmed.ncbi.nlm.nih.gov/37308342/
Satadeve, P. (2025). Comparison of molecular response and safety of lower dose (70 mg) versus standard dose (100 mg) of generic dasatinib in newly diagnosed CML-CP: A randomized controlled study from India. Paper presented at the EHA 2025 Congress. https://www.cml-foundation.org/86-news-icmlf/2333-eha2025-daily-updates-3.html
Shah, N. P., Kantarjian, H., Kim, D.-W., Rea, D., Dorlhiac-Llacer, P., Milone, J. H., ... & Baccarani, M. (2008). Intermittent target inhibition with dasatinib 100 mg once Daily preserves efficacy and improves tolerability in imatinib-resistant and-intolerant chronic-phase chronic myeloid leukemia. Journal of Clinical Oncology, 26(19), 3204–3212. https://doi.org/10.1200/JCO.2007.14.8676
bms india
Written By
Venika Choudhary
Medical Content Writer @ Magicine Pharma
I hold an M.Sc. in Microbiology and have a strong academic foundation in microbial sciences and applied biotechnology. I began my career with extensive hands-on research at CSIR laboratories, focusing on fungal enzyme production, studying fungal diversity in various ecosystems, and developing bio-pesticides as sustainable alternatives to chemical pesticides. This work deepened my understanding of fungal biology, bioactive compounds, and their pharmaceutical and agricultural applications. Transitioning from research, I now work as a medical content writer, where I combine my scientific expertise with a passion for clear and reliable healthcare communication. I apply my research background to create patient-friendly, compliant content for pharmaceutical companies and healthcare platforms, ensuring science is both trustworthy and accessible. Specializing in clear, accurate, and engaging content, I help patients make informed decisions and support pharmaceutical companies in delivering trusted information. Whether writing product descriptions, crafting disease awareness articles, or composing drug information leaflets, I consistently meet regulatory standards and address audience needs, making my content an asset for healthcare brands.
Reviewed By
Dr. Aditya Sarin - MBBS, MD, DrNB - Consultant Medical Oncology
Dr. Aditya Sarin, MBBS, MD, DrNB, is a highly qualified medical oncologist with profound research and clinical expertise, currently working at Sir Ganga Ram Hospital, New Delhi. He is also a member of the European Society of Medical Oncology (ESMO), a non-profit European organization dedicated to eradicating cancer by promoting comprehensive cancer care and advancing medical oncology. He has been honored with several awards, including the International Cancer Foundation scholarship (ESMO congress, 2022) and Young Medical Oncologist of the Year (Times of India, 2024). He is well-known for his breakthrough in oncology. Dr. Sarin is passionate about converting complex health information into a concise and clear form that is understandable to everyone, aiming to create awareness and cancer care among people.